75%Confidence
0Views
FDASource
2026-04-02Date
Summary
Harvard Drug Group's packaging defect for Midodrine tablets reveals potential supply chain vulnerabilities in blister packaging operations, which could affect product integrity and patient adherence. This may impact distributor relationships and necessitate quality system improvements across their product portfolio.
Actionable: Watch for follow-up actions from Major Pharmaceuticals and potential impacts on other products packaged at the same facility.
AI Confidence: 75%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now